Skip to content

Effect and safety evaluation of the anti PD-1 immunotherapy side effect reporting system based on doctor-patient real-time WeChat communication

Effect and safety evaluation of the anti PD-1 immunotherapy side effect reporting system based on doctor-patient real-time WeChat communication

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000031652
Enrollment
Unknown
Registered
2020-04-06
Start date
2020-05-01
Completion date
Unknown
Last updated
2020-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant tumor

Interventions

Group 1:Based on instant wechat communication between doctors and patients
Group 2:Telephone follow-up

Sponsors

The Third Affiliated Hospital of Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Histopathology confirmed malignant tumor; 2. Aged 18-70 years old; 3. Score of physical condition ECOG-ps =3 months; 6. Signed informed consent, able to comply with test requirements.

Exclusion criteria

Exclusion criteria: 1. Suitable for local treatment of patients with recurrent cancer; 2. The last treatment (radiotherapy or chemotherapy) was less than 6 months before admission; 3. With serious cardiopulmonary dysfunction; 4. According to the judgment of the researchers, patients who can't tolerate the treatment of this program; 5. Patients who are allergic to the drugs in the program; 6. Underwent operation or radiotherapy within 21 days; 7. Pregnant or lactating women; 8. Patients who refuse to sign informed consent; 9. Patients who are unable to receive regular treatment and regular follow-up due to psychological, family and geographical reasons; 10. Patients with severe infection, internal diseases, important organ dysfunction and mental disorders; 11. Patients who have undergone other clinical trials within three months.

Design outcomes

Primary

MeasureTime frame
Adverse event;

Secondary

MeasureTime frame
Quality of life;

Countries

China

Contacts

Public ContactXing Li
lixing9@mail.sysu.edu.cn+86 13824408425

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026